TAMPA, FL — In a move that has sparked significant backlash from healthcare advocates and civil rights groups, the Obesity Action Coalition (OAC) has formally called upon PepsiCo to reverse its recent decision to terminate insurance coverage for GLP-1 (glucagon-like peptide-1) medications for obesity. The policy change, which is slated to take effect in October 2026, marks a pivotal moment in the ongoing national debate over how corporate America manages the rising costs of breakthrough weight-loss treatments against its stated commitments to employee health and equity.
n
The OAC, a national nonprofit dedicated to representing individuals affected by obesity, argues that PepsiCo’s decision creates a dangerous precedent, treating a chronic medical condition as an optional lifestyle choice rather than a biological disease. The controversy is further sharpened by PepsiCo’s simultaneous business strategy to market new high-protein products specifically designed for consumers using the very medications the company is now making harder for its own employees to obtain.
n
Main Facts: The Intersection of Cost and Access
n
The core of the dispute centers on the "sustainability" of healthcare benefits. PepsiCo, one of the world’s largest food and beverage conglomerates, reportedly informed its workforce that ending coverage for GLP-1 medications—such as Wegovy and Zepbound—is a necessary step to keep overall healthcare premiums affordable for its broader employee base.
n
However, the OAC and other medical experts contend that this "all-or-nothing" approach to affordability unfairly targets a specific demographic. Obesity affects nearly 42% of the American adult population, and its complications—including Type 2 diabetes, cardiovascular disease, and certain cancers—are among the leading drivers of healthcare spending.
n
“If PepsiCo is committed to protecting healthcare for all employees, that must include employees living with obesity,” stated Joe Nadglowski, OAC President and CEO. “Obesity is a chronic disease, and its treatment should not be singled out for exclusion. By removing coverage, the company is effectively telling a significant portion of its workforce that their health needs are less valid than others.”
n
The transition plan proposed by PepsiCo involves directing employees toward manufacturer-sponsored "self-pay" programs. These programs typically reduce the out-of-pocket cost of GLP-1s to between $300 and $500 per month. While this is a reduction from the $1,000+ list price, the OAC argues it remains a prohibitive barrier for the average worker, essentially rendering the treatment inaccessible for those who do not occupy executive-level positions.
n
Chronology: The Rise of GLP-1s and the Benefit "Cliff"
n
To understand the current friction, one must look at the rapid evolution of obesity treatment over the last three years:
n
- n
- 2023–2024: The GLP-1 Boom. The FDA approvals of medications like Wegovy (semaglutide) and Zepbound (tirzepatide) for chronic weight management revolutionized the field. Unlike previous weight-loss drugs, these medications showed 15% to 22% body weight reduction, leading to a surge in demand.
- 2025: Budgetary Pressures Mount. As millions of Americans sought prescriptions, employer-sponsored insurance plans began to see a massive spike in "pharmacy spend." Many Fortune 500 companies initially covered the drugs but started implementing stricter "prior authorization" requirements to manage costs.
- Early 2026: The Strategic Pivot. PepsiCo, recognizing the massive market of GLP-1 users, began publicizing a shift in its product portfolio. CEO Ramon Laguarta spoke openly about developing "companion products" for GLP-1 users, including protein-enriched snacks and beverages like Propel Clear Protein, to mitigate the "muscle loss" often associated with rapid weight loss.
- September 2, 2026: The Announcement. Reports surfaced that PepsiCo would end obesity-specific GLP-1 coverage for some employee groups starting in October. This sparked the OAC’s immediate call for a reversal, highlighting the disconnect between the company’s consumer marketing and its internal HR policies.
n
n
n
n
n
Supporting Data: The Economics of Obesity Care
n
The financial tension facing PepsiCo is not unique, but the data suggests that cutting coverage may be a short-sighted strategy.
n
The Cost of Treatment
n
The list price for GLP-1 medications generally hovers around $12,000 to $15,000 per year per patient. For a company the size of PepsiCo, with hundreds of thousands of employees, the cumulative cost can reach hundreds of millions of dollars. However, the OAC points out that health plans routinely cover expensive treatments for other chronic conditions, such as rheumatoid arthritis, multiple sclerosis, and various cancers, without the same level of public scrutiny or exclusion.
n
The Cost of Inaction
n
According to the Milken Institute, the total economic burden of obesity in the U.S. exceeds $1.7 trillion annually, including $480 billion in direct healthcare costs and $1.2 trillion in lost productivity. Employees with untreated obesity have higher rates of absenteeism and "presenteeism" (being at work but underperforming due to health issues).
n
Furthermore, a study published in the Journal of Managed Care & Specialty Pharmacy indicates that for every dollar spent on effective obesity treatment, companies see a long-term return through the prevention of expensive secondary conditions like heart failure and kidney disease. By cutting coverage, PepsiCo may be trading immediate pharmacy savings for much larger medical claims down the road.
n
The "Self-Pay" Fallacy
n
The OAC’s critique of the $300–$500 monthly self-pay model is backed by economic reality. For an employee earning a median salary, $6,000 a year in post-tax income dedicated to a single medication is often unsustainable. This creates a "tiering" of health, where only the wealthiest employees can afford the "gold standard" of care, while lower-wage workers are left with older, less effective interventions.
n
Official Responses and Stakeholder Perspectives
n
The OAC’s campaign has ignited a firestorm of responses from various sectors of the healthcare and business communities.
n
The Obesity Action Coalition (OAC):nThe OAC has launched a digital "Action Center," encouraging the public to send messages directly to PepsiCo leadership. "Tell PepsiCo that employees living with obesity deserve equitable access to treatment and that cutting coverage for obesity care is not consistent with a commitment to providing healthcare for all employees," the organization stated in its press release.
n
PepsiCo’s Stance:nWhile PepsiCo has not issued a new comprehensive public statement following the OAC’s call to action, the company’s internal messaging remains focused on "healthcare sustainability." Sources close to the company suggest that the decision was driven by an unprecedented increase in healthcare premiums that threatened to impact the entire workforce’s deductible and co-pay structures.
Medical Experts:
Endocrinologists and obesity specialists have expressed concern that stopping GLP-1 medications abruptly can lead to rapid weight regain and a "rebound" effect in metabolic markers like blood pressure and blood sugar. "This isn’t like stopping a vitamin," says one clinical researcher. "This is a hormonal intervention for a biological disease. Removing access is a clinical disruption that can have serious physical consequences for the patient."
Implications: A High-Stakes Precedent
The PepsiCo situation is being watched closely by HR departments across the globe. As a trendsetter in corporate benefits, PepsiCo’s decision could signal a "green light" for other large employers to slash GLP-1 coverage, or conversely, if the OAC is successful, it could reinforce the necessity of maintaining such benefits.
The Hypocrisy Factor
The most damaging aspect of the controversy for PepsiCo’s brand is the perceived hypocrisy of its business model. By launching products like Propel Clear Protein—specifically marketed to GLP-1 users—the company is essentially profiting from a medical trend while denying its own staff the means to participate in that trend safely and affordably.
"PepsiCo should not view people using GLP-1s as consumers worth investing in while making treatment harder to access for its own employees," the OAC noted. This "double-dipping" strategy—selling the "cure" (companion products) while refusing to pay for the "medicine"—poses a significant PR risk for a company that prides itself on social responsibility.
The Future of Workplace Equity
This conflict also touches on broader themes of workplace equity and weight bias. For decades, obesity was viewed as a personal failure. The advent of GLP-1s helped shift that narrative toward a medical model. By removing coverage, advocates fear that companies are reverting to a bias-driven model where obesity is treated as a "choice" rather than a condition deserving of the same insurance protections as any other illness.
Legal and Regulatory Shadows
There is also the potential for legal challenges. As obesity is increasingly recognized as a disability under certain state laws and the Americans with Disabilities Act (ADA), the targeted removal of effective treatments for a specific group of disabled employees could open the door for litigation.
Conclusion
The Obesity Action Coalition’s challenge to PepsiCo is more than a dispute over a single insurance benefit; it is a battle for the soul of modern employee wellness programs. As October 2026 approaches, the pressure on PepsiCo to align its internal healthcare policies with its external marketing strategies will only intensify.
For the thousands of PepsiCo employees currently relying on these medications to manage their health, the outcome of this standoff will determine whether they can continue their journey toward better health or whether they will be forced to choose between their physical well-being and their financial stability.
The OAC continues to urge individuals to visit www.obesityaction.org to join the call for equitable treatment. As Joe Nadglowski concluded, "Obesity treatment deserves the same consideration as any other life-saving medication. It’s time for PepsiCo to live up to its promise of healthcare for all."
Media Contact:
Gianna Toto
OAC Marketing and Communications Manager
[email protected]
About the OAC:
The Obesity Action Coalition (OAC) is a national nonprofit organization dedicated to improving the lives of individuals affected by obesity through education, advocacy, and support. As the nation’s leading voice for those impacted by obesity, the OAC works to eliminate weight bias and ensure access to science-based treatment.
